Combination therapy with glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: cardiovascular outcomes and emerging evidence. The gene discussed is GLP1R; the disease is diabetes mellitus.